Erika Hamilton’s Highlights from ESMO24

The ESMO Congress 2024 is ongoing in Barcelona, from September 13 to 17, 2024, at the Fira Barcelona Gran Via.

This significant event, organized by the European Society for Medical Oncology (ESMO), attracted over 30,000 participants, including healthcare professionals, researchers, patient advocates, and industry representatives from around the globe.

Erika Hamilton shared some insights from ESMO24:

Nodal radiation for Breast Cancer:

“1265 people who needed nodal radiation for Breast Cancer were randomized to hypofrac XRT 3 weeks vs. normofrac XRT 5 weeks in France 4.8 years follow up – noninferiority of hypofrac radiation  achieved.

No sign of high recurrences.

No worsened lymphedema ~1/3 patients in both arms.”

Key in ‘escalation’ trials

“MonarchE accurately selected a high risk population, key in ‘escalation’ trials! At 5 years with endocrine therapy alone, we see 25% (or 1 in 4 ) have already recurred.”

Big ESMO24 meeting:

“Look who all ran into each other in hall 6 by chance this morning?

Sarah Cannon Docs, SCRI Oncology Partners strong!

At a meeting as big as ESMO24, you are happy when you see your partners!”

MASTERFUL discussion of ILD:

“MASTERFUL discussion of ILD with TDXd by Dr. Pat LoRusso.

HER ‘low’ expression in lung – likely why worse with TDXd than other ADC targets.

Ethnicities such as Japanese at higher risk.

Prior ILD, hepatic and renal impairment all risk factors.”

ADCs in development:

“Think you hear a lot about ADCs now? Just wait….here we go!!!

107 topo1 ADCs in development currently to at least 39 diff.”

Non-nephrotoxic drugs in breast cancer:

“Ok, I know very little about bladder cancer, but how did they get away with CrCl of 40 with a platinum and we often can’t even get CrCl of 50 with non-nephrotoxic drugs in breast cancer?

CrCl of 40 in breast randomized ph III is a zebra.”

KN522 OS Data:

“KN522 OS data 5 years after the initial pCR presentation.

75 months of follow up for chemo +/ pembro I stage II and III TNBC.

EFS is stable from before with 9% improvement with pembro.

OS improved by 5% (81.7-> 86.6%).”

Lower anatomical risk tumors:

“In NATALEE, despite including some lower anatomical risk tumors that were N0…benefit in both the N+ and N -, used other genomic and pathological factors to predict high risk.”

More highlights from ESMO24 on oncodaily.com

Erika Hamilton is a medical oncologist and the Director of Breast Cancer Program at Sarah Cannon Research Institute (USA). Dr. Hamilton is a past chair of ASCO’s Scientific Breast Committee ’21-’22, participant of the ASCO Leadership Development Program, Associate Editor for Clinical Breast Cancer, co-chair for Great Debates and Updates in Women’s Oncology Conference and a board member of the Susan G. Komen Foundation of Central Tennessee.

She is active in the community, volunteering with Gilda’s Club Middle Tennessee, the American Cancer Society’s Hope Lodge, Ovarcome ovarian cancer support organization, Brentwood Baptist Church and the Susan G. Komen Race for the Cure.